Piperaquine Resistance Is Associated with a Copy Number Variation on Chromosome 5 in Drug-Pressured Plasmodium falciparum Parasites
Open Access
- 1 August 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (8) , 3908-3916
Abstract
The combination of piperaquine and dihydroartemisinin has recently become the official first-line therapy in several Southeast Asian countries. The pharmacokinetic mismatching of these drugs, whose plasma half-lives are ∼20 days and ∼1 h, respectively, implies that recrudescent or new infections emerging shortly after treatment cessation will encounter piperaquine as a monotherapy agent. This creates substantial selection pressure for the emergence of resistance. To elucidate potential resistance determinants, we subjected cloned Plasmodium falciparum Dd2 parasites to continuous piperaquine pressure in vitro (47 nM; ∼2-fold higher than the Dd2 50% inhibitory concentration [IC 50 ]). The phenotype of outgrowth parasites was assayed in two clones, revealing an IC 50 against piperaquine of 2.1 μM and 1.7 μM, over 100-fold greater than that of the parent. To identify the genetic determinant of resistance, we employed comparative whole-genome hybridization analysis. Compared to the Dd2 parent, this analysis found (in both resistant clones) a novel single-nucleotide polymorphism in P. falciparum crt ( pfcrt ), deamplification of an 82-kb region of chromosome 5 (that includes pfmdr1 ), and amplification of an adjacent 63-kb region of chromosome 5. Continued propagation without piperaquine selection pressure resulted in “revertant” piperaquine-sensitive parasites. These retained the pfcrt polymorphism and further deamplified the chromosome 5 segment that encompasses pfmdr1 ; however, these two independently generated revertants both lost the neighboring 63-kb amplification. These results suggest that a copy number variation event on chromosome 5 (825600 to 888300) is associated with piperaquine resistance. Transgene expression studies are underway with individual genes in this segment to evaluate their contribution to piperaquine resistance.Keywords
This publication has 60 references indexed in Scilit:
- Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trialThe Lancet Infectious Diseases, 2010
- Genome scanning of Amazonian Plasmodium falciparum shows subtelomeric instability and clindamycin-resistant parasitesGenome Research, 2010
- Spiroindolones, a Potent Compound Class for the Treatment of MalariaScience, 2010
- A Method for Rapid Genetic Integration into Plasmodium falciparum Utilizing Mycobacteriophage Bxb1 Integrase2010
- Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquineProceedings of the National Academy of Sciences, 2009
- Artemisinin Resistance inPlasmodium falciparumMalariaNew England Journal of Medicine, 2009
- Decreasingpfmdr1Copy Number inPlasmodium falciparumMalaria Heightens Susceptibility to Mefloquine, Lumefantrine, Halofantrine, Quinine, and ArtemisininThe Journal of Infectious Diseases, 2006
- An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos)Tropical Medicine & International Health, 2006
- Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integraseNature Methods, 2006
- Human Malaria Parasites in Continuous CultureScience, 1976